Found 72 articles
The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.
Awakn Life Sciences Corp. Announces Completion of Reverse Takeover Transaction, Release from Escrow of Private Placement Proceeds, and Final Approval for Listing on Neo Exchange
The Company has also received final approval to list its common shares on the Neo Exchange Inc. ("NEO"), and trading is expected to commence on June 23, 2021 under the stock symbol "AWKN" (CUSIP: 05455W108).
Awakn Life Sciences to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
Toronto, Ontario--(Newsfile Corp. - June 10, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction...
Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec as Research Partner and Addiction Expert, Prof. David Nutt, as Program Lead
DEFINING CLEAR DEVELOPMENT PATHWAY FOR NEXT GENERATION OF PSYCHEDELIC MEDICINES TO TREAT ADDICTION
Adding significant pharmaceutical and healthcare sector experience and independent board governance to Awakn.
Awakn Launches Digital Unit and Signs Agreement with the University of Exeter to Improve Addiction Treatment Through Artificial Intelligence and Big Data
First project to use advanced analytics to explore identity shifts in alcohol addiction
In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn's next generation psychedelic molecule development programme.
Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) Intervention Validated in a Phase II Clinical Trial
The KARE clinical research study, led by Prof. Celia Morgan of the University of Exeter, was a Phase II a/b, four-armed, placebo-controlled trial assessing ketamine combined with the KARE psychotherapy in the treatment for alcohol use disorder (AUD).
Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World's First 'MDMA in Alcohol Use Disorder' Clinical Trial
Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants.
London, United Kingdom--(Newsfile Corp. - January 25, 2021) - Awakn Life Sciences Inc., a biotechnology company focused on research, development, and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of James Collins as Chief Operating Officer, effective January 2021.
Awakn Strengthens Scientific and Medical Leadership with Appointment of Chief Science Officer and Head of Ketamine Alcohol Use Disorder Practice
Dr. McNulty joins as an experienced biotechnology executive with over 20 years' experience in drug development having previously held positions at Pfizer, GSK, Syntaxin, ImmBio, Biosceptre and Inflection Biosciences.
Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - January 15, 2021) - Awakn Life Sciences announced today the selection of contract research organization ('CRO'), PRA Health Sciences (NASDAQ: PRAH), to conduct a Phase IIb trial studying the effectiveness of MDMA-Assisted Psychotherapy as a treatment for patients with Non-Physically Dependent ('Harmful Use') Alcohol Use Disorder ("AUD").